Egg-Hatching Mechanism of Human Liver Fluke,Opisthorchis viverrini: A Role For Leucine Aminopeptidases From the Snail Host,Bithynia siamensis goniomphalos
Abstract:The human liver fluke Opisthorchis viverrini (Platyhelminthes, Trematoda, Digenea) uses snails of the genus Bithynia as first intermediate host. Peculiarly among trematodes, the eggs of O. viverrini hatch within the digestive tract of its snail host. It remains uncertain whether hatching in this species is mediated through mechanical fracture of the eggshell or by digestion with specific digestive enzymes. This study aimed to characterize enzymes with specific inhibitors and factors involved in the hatching ac… Show more
“…Ubenimex is one of LAP inhibitors that can reduce the activity of LAP, and therefore it can reduce the digestion of liver tissues, fibrogenesis and infiltrative growth (8,47,48). It has also reported that Ubenimex can reduce the invasiveness and damage of other parasites like Leishmania, Human liver fluke, plasmodium by inhibiting the LAP proteins levels (27,49,50). In some malignant tumors, Ubenimex can also inhibit the migration and invasion by alleviating the activity of the LAP (CD13)/NAB1/MAPK pathway (51)(52)(53)(54).…”
IntroductionAlveolar echinococcosis (AE) is a parasitic disease caused by E. multilocularis metacestodes and it is highly prevalent in the northern hemisphere. We have previously found that vaccination with E. multilocularis-Leucine aminopeptidase (EM-LAP) could inhibit the growth and invasion of E. multilocularis in host liver, and Ubenimex, a broad-spectrum inhibitor of LAP, could also inhibit E. multilocularis invasion but had a limited effect on the growth and development of E. multilocularis.MethodsIn this study, the therapeutic effect of Ubenimex combined with Albendazole on AE was evaluated. Mice were intraperitoneally injected with protoscoleces and imaging examination was performed at week 8 and week 16 to detect cyst change. During this period, mice were intraperitoneally injected with Ubenimex and intragastrically administered with Albendazole suspension. At last, the therapeutic effect was evaluated by morphological and pathological examination and liver function.ResultsThe results revealed that the combined treatment could inhibit the growth and infiltration of cysts in BALB/c mice infected with E. multilocularis protoscoleces. The weight, number, invasion and fibrosis of cysts were reduced in mice treated with Ubenimex in combination with Albendazole. The same effect was achieved by the single Ubenimex treatment because of its inhibitory effect on LAP activity, but it was less effective in inhibiting the growth of cysts. The levels of ALT, AST, TBIL, DBIL, ALP, and γ-GT were reduced after the combined treatment, indicating that treatment with both Ubenimex and Albendazole could alleviate liver damage.DiscussionThis study suggests that the combined treatment with Ubenimex and Albendazole could be a potential therapeutic strategy for E. multilocularis infections.
“…Ubenimex is one of LAP inhibitors that can reduce the activity of LAP, and therefore it can reduce the digestion of liver tissues, fibrogenesis and infiltrative growth (8,47,48). It has also reported that Ubenimex can reduce the invasiveness and damage of other parasites like Leishmania, Human liver fluke, plasmodium by inhibiting the LAP proteins levels (27,49,50). In some malignant tumors, Ubenimex can also inhibit the migration and invasion by alleviating the activity of the LAP (CD13)/NAB1/MAPK pathway (51)(52)(53)(54).…”
IntroductionAlveolar echinococcosis (AE) is a parasitic disease caused by E. multilocularis metacestodes and it is highly prevalent in the northern hemisphere. We have previously found that vaccination with E. multilocularis-Leucine aminopeptidase (EM-LAP) could inhibit the growth and invasion of E. multilocularis in host liver, and Ubenimex, a broad-spectrum inhibitor of LAP, could also inhibit E. multilocularis invasion but had a limited effect on the growth and development of E. multilocularis.MethodsIn this study, the therapeutic effect of Ubenimex combined with Albendazole on AE was evaluated. Mice were intraperitoneally injected with protoscoleces and imaging examination was performed at week 8 and week 16 to detect cyst change. During this period, mice were intraperitoneally injected with Ubenimex and intragastrically administered with Albendazole suspension. At last, the therapeutic effect was evaluated by morphological and pathological examination and liver function.ResultsThe results revealed that the combined treatment could inhibit the growth and infiltration of cysts in BALB/c mice infected with E. multilocularis protoscoleces. The weight, number, invasion and fibrosis of cysts were reduced in mice treated with Ubenimex in combination with Albendazole. The same effect was achieved by the single Ubenimex treatment because of its inhibitory effect on LAP activity, but it was less effective in inhibiting the growth of cysts. The levels of ALT, AST, TBIL, DBIL, ALP, and γ-GT were reduced after the combined treatment, indicating that treatment with both Ubenimex and Albendazole could alleviate liver damage.DiscussionThis study suggests that the combined treatment with Ubenimex and Albendazole could be a potential therapeutic strategy for E. multilocularis infections.
“…Egg hatching is a complex process that involves multiple synergies including neuronal activity, hormone secretion, protease synthesis and energy metabolism (Khampoosa et al, 2018; Konopová et al, 2020). Injecting corticotropin‐releasing hormone into the egg embryos of domestic chickens ( Gallus gallus ) results in the release of adrenocorticosteroids and thyroid hormones, speeding up egg hatching (Watanabe et al, 2017).…”
Section: Discussionmentioning
confidence: 99%
“…Egg hatching is a complex process that involves multiple synergies including neuronal activity, hormone secretion, protease synthesis and energy metabolism (Khampoosa et al, 2018;Konopová et al, 2020). Injecting F I G U R E 7 The putative pathway that the circadian clock regulates hatching rhythm of silkworm.…”
The hatching of insect eggs is a classic circadian behavior rhythm controlled by the biological clock. Its function is considered to impose a daily rhythm on the embryo, allowing it to hatch within a permissible time window. However, the molecular pathways through which the clock affects embryonic hatching behavior remain unclear. Here, we utilized a clock gene Cryptochrome1 (Cry1) knockout mutant to dissect the pathways by which the circadian clock affects embryonic hatching rhythm in the silkworm. In the Cry1 mutant, the embryo hatching rhythm was disrupted. Under the constant light or constant dark incubation conditions, mutant embryos lost their hatching rhythm, while wild‐type embryos hatch exhibiting free‐running rhythm. In the light‐dark cycle (LD), the hatching rhythm of CRY1‐deficient silkworms could not be entrained by the LD photoperiod during the incubation period. The messenger RNA levels and enzymatic activities of Cht and Hel in the mutant embryos were significantly reduced at circadian time 24 (CT24). Transcriptome analysis revealed significant differences in gene expression at CT24 between the Cry1 knockout mutant and the wild‐type, with 2616 differentially expressed genes identified. The enriched Gene Ontology pathway includes enzyme activity, energy availability, and protein translation. Short neuropeptide F signaling was reduced in the CT24 embryonic brain of the mutant, the expression of the neuropeptide PTTH was also reduced and the rhythm was lost, which further affects ecdysteroid signaling. Our results suggested that the silkworm circadian clock affects neuropeptide‐hormone signaling as well as physiological functions related to hatching, which may regulate the hatching rhythm.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.